Yahoo Finance·2025-12-18 09:10Core Insights - Eli Lilly and Novo Nordisk are leading companies in the GLP-1 weight loss market, with strong long-term growth prospects due to their innovative products [1] - Eli Lilly's stock has increased by 35% over the past year, while Novo Nordisk's stock has decreased by 53% [2] Eli Lilly - Eli Lilly has achieved a market capitalization of over $1 trillion, becoming the first healthcare company to reach this milestone [4] - The company's GLP-1 drugs, Mounjaro and Zepbound, generated $25 billion in revenue in the first nine months of the year, accounting for more than half of its total sales of $46 billion [5] - Zepbound has shown superior effectiveness in weight loss compared to Novo Nordisk's Wegovy, with an average weight loss of 20.2% versus 13.7% in a 72-week trial [6] - Eli Lilly's stock has increased by over 570% in the past five years, indicating strong growth potential [7] Novo Nordisk - Novo Nordisk has faced challenges, including a change in leadership and a reduction in guidance due to competition from compounded drug versions, leading to a decline in its stock price [8] - Despite recent difficulties, there is optimism for a turnaround, as the stock is currently trading at a low valuation of 14 times its trailing earnings, compared to Eli Lilly's P/E ratio of over 50 [10] - The current lower expectations for Novo Nordisk may present a buying opportunity for investors [10]